Our findings highlight the importance of optimizing the dose when testing a new adjuvant/antigen formulation since the optimal efficacy of the vaccine clearly depends both on the dose of the antigen and the adjuvant used.
Results at 1 year revealed that optimal efficacy and safety were achieved with a regimen containing tacrolimus+MMF.
Although these approaches are certainly promising for AD therapeutics, further study is needed to identify ideal stem cell candidates and define dosing and delivery parameters for optimal efficacy in patients.
To identify the optimal quantity of warming moxibustion Tianshu (ST 25, bilateral) and Qihai (CV 6) to achieve optimal efficacy.
However, pre-existing antibodies present a significant limitation to achieving optimal efficacy for the AAV gene delivery system.
As a consequence, currently used dosing regimens may not assure optimal efficacy or minimal toxicity in these patients.
In vivo ocular anti-inflammatory efficacy test confirmed an optimal efficacy of NPs and its potential application in eye surgery.
This allows for new types of therapeutic modalities engineered for optimal efficacy on the molecular target in the brain independent of brain penetrating properties.
We establish that, among our engineered multiepitopic formats, trans-triepitopic antibody fusions demonstrate optimal efficacy, inducing rapid EGFR clustering and internalization and consequently ablating downstream signaling.
Our results indicate that a number of parameters, including treatment starting day, dose level, and dose frequency, are critical in achieving the optimal efficacy of ING-1 heMAb). ING-1 heMAb
Rapid rate of absorption is suggested to be important for optimal efficacy.
